Lowering the number or lowering the risk?


9th November 2026

Newsletter Monday

Reader

Some time ago, I wrote a post about those cholesterol-lowering spreads you can buy in the supermarket.

You know the ones. Benecol and its team mates.

The central claim made about these products isn’t false. They contain plant sterols, which have been shown to lower LDL cholesterol.

However, despite being around for decades, we don’t see good evidence from clinical trials that using these products reduces your chances of having a heart attack or stroke.

And I made the point at the time that human biology is complex. Beautifully so.

It’s perfectly understandable to assume that if something is known to cause harm, reducing it must automatically produce a benefit.

But medicine and human physiology doesn’t always work like that.

Which brings me to a rather interesting trial that caught my eye last week.

You probably won’t see too many headlines about this one.

Nobody can jump up and down celebrating a new breakthrough, and there’s not much opportunity to sell you something on the back of it.

But as I’ve said before, negative findings in clinical trials are just as important as positive ones.

They just don’t make particularly good headlines.

Have you heard of Lp(a)?

Lipoprotein(a), usually shortened to Lp(a), is a particle in your blood that carries cholesterol.

Higher levels are associated with an increased risk of cardiovascular disease.

Unlike LDL cholesterol, which we can influence through diet and medication, your Lp(a) level is largely determined by your genes.

You can’t meaningfully lower it by eating more vegetables, going for a run or losing a few pounds.

Now, if you’ve been tempted by the growing market for private blood testing, particularly the increasingly fashionable world of biomarkers and personalised health assessments, you may have come across Lp(a).

Dr Rangan Chatterjee’s Do Health, which I’ve mentioned before, includes Lp(a) in its testing and has promoted its value in helping people understand their cardiovascular risk.

And that’s where I start to have a problem with the marketing of these tests.

Because there’s a difference between measuring something that predicts your risk of disease and being able to do something meaningful about it.

When you sell people tests on the promise of giving them greater insight into their health, there’s an implication that this knowledge will allow them to take control of their future.

But what happens when the thing you’ve measured is largely genetically determined?

You can recommend lifestyle changes, of course. Eat well, exercise, manage your weight, don’t smoke.

All excellent advice.

But none of those things will substantially lower your Lp(a).

And you didn’t need to pay for a private blood test to know they were good ideas.

In fact, I recently recorded a podcast with Dr Margaret McCartney, who successfully challenged some of Do Health’s advertising claims through the Advertising Standards Authority.

The ASA ruled that the advertising was misleading because it suggested that blood testing could help prevent serious diseases and provide personalised health advice without sufficient evidence to support those claims.

It’s worth being clear that the ruling wasn’t specifically about Lp(a). But it illustrates a much wider problem with the way health testing is being sold.

Which brings me back to the trial.

Researchers have been investigating a drug called pelacarsen, designed specifically to lower Lp(a).

The trial involved around 8,300 people who already had cardiovascular disease and elevated Lp(a) levels.

Half received the drug, while the others received a placebo.

And the drug worked extraordinarily well at doing what it was designed to do.

It lowered Lp(a) by approximately 78%.

That’s a huge reduction.

So you’d reasonably expect that people receiving the drug would go on to have fewer heart attacks, strokes and other cardiovascular events.

Except they didn’t.

After nearly five years of follow-up, the rates of major cardiovascular events were virtually identical between the two groups.

12.3% in the treatment group compared with 12.1% in the placebo group.

Despite dramatically lowering a substance known to contribute to cardiovascular disease, the drug didn’t improve the outcomes that actually matter to patients.

Now, that doesn’t mean Lp(a) is irrelevant.

Nor does it mean that lowering it could never be beneficial.

This was one particular drug, tested in people who already had cardiovascular disease.

But it does demonstrate something important.

Changing a number on a blood test isn’t necessarily the same as changing someone’s future.

And I think that’s worth remembering as the market for private health testing continues to grow.

I’m not suggesting that measuring Lp(a) is never useful. In clinical practice, knowing someone has a particularly high level can influence how we assess their overall cardiovascular risk and how aggressively we manage other risk factors, particularly LDL cholesterol.

But that’s quite different from the suggestion that the more biomarkers you measure, the more control you have over your health.

And I think we should be asking much harder questions of companies selling these tests.

What exactly will someone do differently with this information?

Is there good evidence that those actions will improve their health?

And would they have benefited from the same advice without paying for the test in the first place?

Because there’s a growing commercial industry built around the idea that more information about our bodies must be better.

  • More tests.
  • More biomarkers.
  • More numbers to watch.

But more information doesn’t automatically mean better health.

There is still an enormous amount we don’t understand about human biology.

And I rather like that. It keeps science interesting and occasionally reminds us that we’re not nearly as clever as we think we are.

In the meantime, I’ll continue doing the things that have consistently been shown to improve our health.

And perhaps we could stop turning every trip to the supermarket into a medical consultation.

Sometimes you just want something to put on your toast.

Remember your body is the greatest thing you will ever own.

Look after it, train it and keep moving.

Thank you for reading.

See you same time, next week.

Lynette

P.s Thank you to those reply to my emails, I love to hear your feedback, but unfortunately can't respond to everyone.

​

Catch the latest podcast episode

Listen to my conversation with Matt Hussey, learn how to spot a grifter

video preview​
show
How to spot a grifter with M...
Nov 3 · The Prescription Strengt...
62:51
Spotify Logo
 
​

LE8 9EF. Leicestershire.
​Unsubscribe · Preferences​

Prescription Strength

Health headlines without the hype. A weekly dose of medical insight, common sense and occasional sarcasm from a GP who’s seen it all

Read more from Prescription Strength

2nd November 2026 Newsletter Monday Just hilarious I spent last night laughing until my face hurt at Kevin Bridges who performed at Nottingham arena, and I’m still laughing about some of his jokes this morning. I’m mentioning it here because, amongst all that humour, were some rather sharp observations that connected with things I’d been thinking about over the weekend. On Saturday, I listened to Harvard evolutionary biologist Daniel Lieberman talking to Michael Easter on his podcast about...

26th October 2026 Newsletter Monday Another day, another headline Do you remember the time when we knew remarkably little about the health of famous people? Occasionally, a celebrity’s health would become mainstream news. Perhaps a well-known actor had developed cancer, or a musician had a condition serious enough to threaten their career. Otherwise, their medical histories were largely their own business. Perhaps something might have been revealed during an interview with Michael Parkinson...

19th October 2026 Newsletter Monday The reality of our corridors Hello Reader, On a recent home visit, I went to see a man in his late 90s. The complaint was painful legs. He lived alone, with carers visiting twice a day. When I arrived, I found him dozing in his chair, surrounded by the essentials of his daily life. Everything he needed was within reach. His phone, TV remote, snacks, drinks and urine bottle. The only reasons he needed to get up were to go to bed or use the toilet for a poo....